Depression is a term which state of low mood (mood disorder) and repugnance to activity that can affect a person's thoughts, behavior, feelings and sense of well-being. People with de¬pressed mood can persistent feeling of sadness and loss of interest, worthless, anxious, empty, hopeless, helpless, guilty, irritable, ashamed or restless. They may lose interest in activities that were once pleasurable, experience loss of appetite or overeating, have problems concen¬trating, remembering details or making decisions, and may contemplate, attempt or commit suicide. Insomnia, aches, pains, digestive problems, excessive sleeping or reduced energy may also be present. You may have trouble doing normal day-to-day activities, and sometimes you may feel as if life isn't worth living.
Anti–Depressent increased the risk compared to placebo of suicidal thinking and behavior (sui¬cidality) in children, adolescents, and young adults. Transdermal delivery of venlafaxine hydrochlo¬ride (VHCl) may result in proper patient compliance by reducing the incidence of the undesirable GI problems generally associated with its plural oral dosing. In therapeutic dosing with VHCl tablets, rapid dissolution results in rapid increase in plasma levels of active com¬pounds shortly after administration followed by a decrease in blood plasma levels over several hours as the active compound is eliminated or metabolized, until sub-therapeutic levels are ap-proached after about 12 hrs, following administration, thus require additional dosing with the drug. With plural daily dosing regimen, the most common side effect is nausea, experienced by 45% of patients under treatment with VHCl. About 17% of the pa¬tients suffers from vomiting at higher doses VHCl is associated with a rise in blood pressure. There is no first pass metabolism effect on drug absorbed through transdermal route while oral drugs are metabolized in liver. Hence, this enhance the greater uniformity in plasma levels in case of TDDS and also reduces toxicity.